BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893. [PMID: 20683932 DOI: 10.1002/hep.23785] [Cited by in Crossref: 627] [Cited by in F6Publishing: 596] [Article Influence: 52.3] [Reference Citation Analysis]
Number Citing Articles
1 Kuo L, Lee C, Hung C, Wang J, Hu T, Lu S, Changchien C, Chen C. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Dig Dis Sci 2014;59:2580-7. [DOI: 10.1007/s10620-014-3194-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
4 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 165.6] [Reference Citation Analysis]
5 Tong MJ, Kowdley KV, Pan C, Hu KQ, Chang TT, Han KH, Yoon SK, Goodman ZD, Beebe S, Iloeje U. Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir. Liver Int. 2013;33:650-651. [PMID: 23489906 DOI: 10.1111/liv.12121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Man Cho S, Choe BH. Treatment strategies according to genotype for chronic hepatitis B in children. Ann Transl Med 2016;4:336. [PMID: 27761440 DOI: 10.21037/atm.2016.09.06] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation. 2014;97 Suppl 8:S53-S59. [PMID: 24849836 DOI: 10.1097/01.tp.0000446278.43804.f9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
8 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
9 Nkongolo S, Hollnberger J, Urban S. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35028672 DOI: 10.1007/s00103-022-03486-2] [Reference Citation Analysis]
10 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
11 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Bae M, Park YK, Lee JY. Food components with antifibrotic activity and implications in prevention of liver disease. J Nutr Biochem 2018;55:1-11. [PMID: 29268106 DOI: 10.1016/j.jnutbio.2017.11.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
13 Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015; 7(22): 2404-2410 [PMID: 26464756 DOI: 10.4254/wjh.v7.i22.2404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
14 Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015;87:1989-99. [PMID: 25989114 DOI: 10.1002/jmv.24270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
15 Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475. [PMID: 23234725 DOI: 10.1016/s0140-6736(12)61425-1] [Cited by in Crossref: 1004] [Cited by in F6Publishing: 400] [Article Influence: 100.4] [Reference Citation Analysis]
16 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
17 Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143-151.e5. [PMID: 24704525 DOI: 10.1053/j.gastro.2014.03.048] [Cited by in Crossref: 192] [Cited by in F6Publishing: 191] [Article Influence: 24.0] [Reference Citation Analysis]
18 Ghany MG. Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31:299-309. [PMID: 28774412 DOI: 10.1016/j.bpg.2017.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
19 Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281. [PMID: 27639844 DOI: 10.1016/j.jhep.2016.08.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 14.5] [Reference Citation Analysis]
20 Yoon JH, Lee JM, Joo I, Lee ES, Sohn JY, Jang SK, Lee KB, Han JK, Choi BI. Hepatic Fibrosis: Prospective Comparison of MR Elastography and US Shear-Wave Elastography for Evaluation. Radiology 2014;273:772-82. [DOI: 10.1148/radiol.14132000] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 13.3] [Reference Citation Analysis]
21 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
23 Viganò M, Mangia G, Lampertico P. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Liver Int 2014;34 Suppl 1:120-6. [PMID: 24373088 DOI: 10.1111/liv.12401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
24 Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Xu Y, Xie W, Li H, Feng B, Shi G, Chen G, Li H, Zheng H, Cheng J, Wang T, Liu H, Lv F, Shao C, Mao Y, Sun J, Chen T, Han T, Han Y, Wang L, Ou X, Zhang H, Jia J, You H. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat. 2019;26:576-585. [PMID: 30624000 DOI: 10.1111/jvh.13058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
25 Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol 2020;18:457-467.e21. [PMID: 31306800 DOI: 10.1016/j.cgh.2019.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
26 Elhosary YA, Saleh SM, Ezzat WM, Clevert DA. Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) in Diagnosis of Liver Fibrosis among Egyptian Patients with Chronic HCV Infection. Open Access Maced J Med Sci 2016;4:374-80. [PMID: 27703558 DOI: 10.3889/oamjms.2016.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Muqit MK, Stanga PE, Vilar FJ, Patton N. Presumed entecavir-induced ocular toxicity. Eye (Lond) 2011;25:1665-8. [PMID: 22020173 DOI: 10.1038/eye.2011.259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Asselah T, Marcellin P. Long-term Results of Treatment with Nucleoside and Nucleotide Analogues (Entecavir and Tenofovir) for Chronic Hepatitis B. Clinics in Liver Disease 2013;17:445-50. [DOI: 10.1016/j.cld.2013.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
30 Lo GH. Higher viral load, higher hepatitis B surface antigen clearance? Hepatology 2014;59:2427. [PMID: 24919452 DOI: 10.1002/hep.26900] [Reference Citation Analysis]
31 Wang PP, Xie DY, Liang XJ, Peng L, Zhang GL, Ye YN, Xie C, Gao ZL. HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. PLoS One. 2012;7:e43408. [PMID: 22927965 DOI: 10.1371/journal.pone.0043408] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
32 Hsieh YH, Huang HC, Chang CC, Chuang CL, Lee FY, Hsu SJ, Huang YH, Hou MC, Lee SD. Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat. J Pharmacol Exp Ther 2018;367:260-6. [PMID: 30194095 DOI: 10.1124/jpet.118.250431] [Reference Citation Analysis]
33 Liu T, Sun Y, Zhou J, Yang F, Zou X, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Wang T, Ou X, Wu S, Kong Y, Wang P, Cong M, Zhang Y, You H, Jia J. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy. J Med Virol 2019;91:1499-509. [PMID: 30905065 DOI: 10.1002/jmv.25465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
35 Lok AS. Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:199-200. [PMID: 23358397 DOI: 10.1038/nrgastro.2013.13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
36 Huang AJ, Núñez M. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression. J Int Assoc Provid AIDS Care 2015;14:360-8. [PMID: 25999329 DOI: 10.1177/2325957415586258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
37 Rinaldi L, Ascione A, Messina V, Rosato V, Valente G, Sangiovanni V, Zampino R, Marrone A, Fontanella L, de Rosa N, Orabona P, Buonomo C, Chirianni A, Adinolfi LE, Piai G. Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection 2018;46:231-8. [PMID: 29335905 DOI: 10.1007/s15010-017-1113-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
38 Xie ZB, Wang XB, Fu DL, Zhong JH, Yang XW, Li LQ. Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. Onco Targets Ther 2016;9:4593-603. [PMID: 27524913 DOI: 10.2147/OTT.S104300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 An J, Kim KW, Han S, Lee J, Lim YS. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418-1426. [PMID: 24754260 DOI: 10.1111/apt.12771] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
40 Buti M. HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs? Liver Int 2014;34:108-11. [DOI: 10.1111/liv.12392] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
41 Park CH, Jung SW, Shin JW, Bae MA, Lee YI, Park YT, Chung HS, Park NH. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 2016;22:152-9. [PMID: 27044766 DOI: 10.3350/cmh.2016.22.1.152] [Reference Citation Analysis]
42 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
43 Li HM. Liver regeneration microenvironment in liver cancer: Research progress and prospect. Shijie Huaren Xiaohua Zazhi 2018; 26(26): 1529-1536 [DOI: 10.11569/wcjd.v26.i26.1529] [Reference Citation Analysis]
44 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
45 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. United European Gastroenterol J 2018;6:1391-400. [PMID: 30386612 DOI: 10.1177/2050640618791053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
47 Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, Lai CL, Yuen MF. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071-1079. [PMID: 27659292 DOI: 10.1111/apt.13804] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
48 Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol 2015; 21(43): 12421-12429 [PMID: 26604649 DOI: 10.3748/wjg.v21.i43.12421] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Beyond “Cirrhosis”: A Proposal From the International Liver Pathology Study Group. Am J Clin Pathol 2012;137:5-9. [DOI: 10.1309/ajcp2t2ohtapbtmp] [Cited by in Crossref: 63] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
50 Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol 2013;305:C789-99. [PMID: 23903700 DOI: 10.1152/ajpcell.00230.2013] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 16.0] [Reference Citation Analysis]
51 Vlachogiannakos J, Papatheodoridis GV. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int 2015;35:100-6. [DOI: 10.1111/liv.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
52 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19(47): 8822-8830 [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
53 Su T, Kao J. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:141-54. [DOI: 10.1586/17474124.2015.960398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
54 Benias PC, Min AD. Goals of Antiviral Therapy for Hepatitis B: HBeAg Seroconversion, HBsAg Seroconversion, Histologic Improvement, and Possible Impact on Risk of Hepatocellular Carcinoma. Curr Hepatitis Rep 2011;10:292-6. [DOI: 10.1007/s11901-011-0112-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 van Bömmel F, Berg T. Treatment of HBV related cirrhosis. Liver Int. 2013;33 Suppl 1:176-181. [PMID: 23286862 DOI: 10.1111/liv.12074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
56 Lei X, Ouyang H. Image segmentation algorithm based on improved fuzzy clustering. Cluster Comput 2019;22:13911-21. [DOI: 10.1007/s10586-018-2128-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Cho HJ, Kim B, Lee JD, Kang DR, Kim JK, Lee JH, Shin SJ, Lee KM, Yoo BM, Lee KJ. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. Am J Gastroenterol. 2017;112:460-470. [PMID: 27779194 DOI: 10.1038/ajg.2016.480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
58 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
59 Rockey DC. Liver Fibrosis Reversion After Suppression of Hepatitis B Virus. Clin Liver Dis. 2016;20:667-679. [PMID: 27742006 DOI: 10.1016/j.cld.2016.06.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
60 Zoulim F, Testoni B, Lebossé F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies. Clin Gastroenterol Hepatol. 2013;11:1011-1013. [PMID: 23602824 DOI: 10.1016/j.cgh.2013.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
61 Chang H, Tsai H, Teng C, Hui-ching Wang L, Huang W, Su I; 1 Department of Biotechnology, Southern Taiwan University of Science and Technology, Taiwan, 2 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 3 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, 4 Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan, 5 Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan, 6 Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. . AIMS Medical Science 2018;5:90-101. [DOI: 10.3934/medsci.2018.2.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
63 Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Reference Citation Analysis]
64 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
66 Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y, Huang F, Liu Z, Rajani C, Zheng X, Qiu J, Zhang X, Zhao S, Bian H, Gao X, Sun B, Jia W. Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine 2021;66:103290. [PMID: 33752128 DOI: 10.1016/j.ebiom.2021.103290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography. 2017;36:86-94. [PMID: 27956732 DOI: 10.14366/usg.16023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
68 Kim SS, Ahn EK, Cho SY, Park RW, Cho HJ, Kim JH, Kim HG, Lee GR, Hwang SH, Yang MJ, Cheong JY, Cho SW. Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e11087. [PMID: 29901622 DOI: 10.1097/MD.0000000000011087] [Reference Citation Analysis]
69 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
70 Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, Ma W, Chen LP, Tseng YJ, Wang JY, Shen XZ, Jiang W. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med. 2018;18:433-443. [PMID: 29696462 DOI: 10.1007/s10238-018-0501-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
71 Han E, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Kim SU. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:300-12. [PMID: 29920701 DOI: 10.1111/apt.14843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
72 Urata Y, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, Sakae M, Kaneda K, Ohata K, Nozawa A. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685-696. [PMID: 22203455 DOI: 10.1007/s00534-011-0489-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
73 Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571. [PMID: 28122837 DOI: 10.1136/bmjopen-2016-014571] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
74 Zeng DB, Di L, Zhang RC, Guo QL, Duan BW, Jia CY, Chen F, Lin DD, Zang YJ, Lu SC. The Effect of Splenectomy on the Reversal of Cirrhosis: a Prospective Study. Gastroenterol Res Pract. 2019;2019:5459427. [PMID: 31093275 DOI: 10.1155/2019/5459427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Brown RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu C, Buti M, Fagan EA. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. Journal of Hepatology 2012;57:953-9. [DOI: 10.1016/j.jhep.2012.06.031] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
76 Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56:1171-1180. [PMID: 22245903 DOI: 10.1016/j.jhep.2011.09.024] [Cited by in Crossref: 253] [Cited by in F6Publishing: 243] [Article Influence: 25.3] [Reference Citation Analysis]
77 Ho MJ, Lee DR, Im SH, Yoon JA, Shin CY, Kim HJ, Jang SW, Choi YW, Han YT, Kang MJ. Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. Eur J Pharm Biopharm 2018;130:143-51. [PMID: 29940226 DOI: 10.1016/j.ejpb.2018.06.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
78 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
79 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
80 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
81 Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, Yoon JH. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat 2018;25:1161-71. [PMID: 29741286 DOI: 10.1111/jvh.12927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
82 Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio K, Fujino H, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. Hepatol Res 2018;48:264-74. [PMID: 29114970 DOI: 10.1111/hepr.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
83 Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606 [PMID: 26327767 DOI: 10.3748/wjg.v21.i32.9598] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
84 Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-2063. [PMID: 24954675 DOI: 10.1016/s0140-6736(14)60220-8] [Cited by in Crossref: 809] [Cited by in F6Publishing: 403] [Article Influence: 101.1] [Reference Citation Analysis]
85 Hsu L, Bowlus CL, Stewart SL, Nguyen TT, Dang J, Chan B, Chen MS Jr. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci 2013;58:807-14. [PMID: 23073671 DOI: 10.1007/s10620-012-2396-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
86 Koh YH, Ong JHY, McCartney E, Morgan J, Narayana S, Tse E. Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting. Intern Med J 2020;50:177-84. [PMID: 31449717 DOI: 10.1111/imj.14622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
88 Andersen ES, Weiland O, Leutscher P, Krarup H, Westin J, Moessner B, Konopski Z, Frigstad SO, Kjær M, Christensen PB, Weis N. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol 2011;46:760-6. [PMID: 21438780 DOI: 10.3109/00365521.2011.565068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
89 Yu JH, Jin Y, Lee J, Lee D. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea: HCC risk in CHB patients. Hepatol Res 2018;48:862-71. [DOI: 10.1111/hepr.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
90 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
91 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
92 Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 2013;33 Suppl 1:111-115. [PMID: 23286854 DOI: 10.1111/liv.12057] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
93 Rong G, Chen Y, Yu Z, Li Q, Bi J, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chen Y, Dong Z, Bai W, Yoshida EM, Mendez-Sanchez N, Hu KQ, Qi X, Yang Y. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. J Infect Dis 2020:jiaa266. [PMID: 32437567 DOI: 10.1093/infdis/jiaa266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. Journal of Hepatology 2013;59:814-29. [DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 13.4] [Reference Citation Analysis]
95 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
96 Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, Seto WK, Fung J, Lai CL, Yuen MF. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol 2019;34:1817-23. [PMID: 30786068 DOI: 10.1111/jgh.14637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
97 Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study. Dig Dis Sci 2014;59:168-73. [DOI: 10.1007/s10620-013-2940-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
98 Wong GL, Chan HL, Yu Z, Chan H, Tse C, Wong VW. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination: Fibrosis progression in hepatitis B. J Gastroenterol Hepatol 2013;28:1762-9. [DOI: 10.1111/jgh.12312] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
99 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
100 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
101 Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol 2015; 7(8): 1064-1073 [PMID: 26052395 DOI: 10.4254/wjh.v7.i8.1064] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
102 Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat. 2011;18:e200-e205. [PMID: 21692933 DOI: 10.1111/j.1365-2893.2010.01428.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
103 Marcellin P. Le traitement a un impact positif sur l’évolution à long terme de l’hépatite chronique B. Gastroentérologie Clinique et Biologique 2010;34:S99-S102. [DOI: 10.1016/s0399-8320(10)70027-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Masaki N, Shrestha PK, Nishimura S, Ito K, Sugiyama M, Mizokami M. Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital. Hepatol Res 2015;45:1163-9. [PMID: 25581418 DOI: 10.1111/hepr.12482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
106 Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y, Zhang X. Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels. Clin Chim Acta. 2012;413:1796-1799. [PMID: 22796373 DOI: 10.1016/j.cca.2012.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
107 Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S, Zuk A, Arbeeny C, Ledbetter S. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One 2013;8:e54499. [PMID: 23349909 DOI: 10.1371/journal.pone.0054499] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
108 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
109 Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, Marra F, Laffi G, Milani S, Zignego AL. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. Eur J Pharmacol. 2017;806:105-109. [PMID: 28414057 DOI: 10.1016/j.ejphar.2017.03.063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
110 Ibragimov EK, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Odintsov AV, Panevkina SV, Moiseev SV. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Ter Arkh 2019;91:40-7. [PMID: 31094170 DOI: 10.26442/ 00403660.2019.02.000073] [Reference Citation Analysis]
111 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014;20:401-13. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Reference Citation Analysis]
112 Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Lv F, Shao C, Wang T, Ou X, Wang B, Chen S, Wee A, Theise ND, You H, Jia J. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438-1450. [PMID: 28027574 DOI: 10.1002/hep.29009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
113 Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis 2021;21:823-33. [PMID: 33524314 DOI: 10.1016/S1473-3099(20)30692-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
114 Tana MM, Hoofnagle JH. Scar undone: long-term therapy of hepatitis B. Lancet 2013;381:433-4. [PMID: 23234726 DOI: 10.1016/S0140-6736(12)61721-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
115 Facciorusso A, Garcia Perdomo HA, Muscatiello N, Buccino RV, Wong VW, Singh S. Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B. Dig Liver Dis 2018;50:787-94. [PMID: 29807871 DOI: 10.1016/j.dld.2018.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
116 Cai FF, Wu R, Song YN, Xiong AZ, Chen XL, Yang MD, Yang L, Hu Y, Sun MY, Su SB. Yinchenhao Decoction Alleviates Liver Fibrosis by Regulating Bile Acid Metabolism and TGF-β/Smad/ERK Signalling Pathway. Sci Rep 2018;8:15367. [PMID: 30337590 DOI: 10.1038/s41598-018-33669-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
117 Dai W, Liu Y, Zhang Y, Sun Y, Sun C, Zhang Y, Lv X. Expression of neuropeptide Y is increased in an activated human HSC cell line. Sci Rep 2019;9:9500. [PMID: 31263154 DOI: 10.1038/s41598-019-45932-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Xie W, Shi GF, Zhang HF, Zhao GM, Yu ZJ, Lang ZW, Zhao H, Yan J, Cheng J. A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int. 2012;6:441-448. [PMID: 21773778 DOI: 10.1007/s12072-011-9294-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
119 Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
120 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
121 Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
122 Lo GH. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with cirrhosis: facts or fiction? Hepatology 2014;60:1797. [PMID: 24519364 DOI: 10.1002/hep.27073] [Reference Citation Analysis]
123 Kim MN, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 2014;34:1216-1223. [PMID: 24267737 DOI: 10.1111/liv.12377] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
124 Pawłowska M, Halota W, Smukalska E, Woźniakowska-Gęsicka T, Kupś J. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2012;31:571-4. [PMID: 21796345 DOI: 10.1007/s10096-011-1349-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
125 Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63:319-333. [PMID: 26565396 DOI: 10.1002/hep.28302] [Cited by in Crossref: 179] [Cited by in F6Publishing: 168] [Article Influence: 25.6] [Reference Citation Analysis]
126 Wangler J, Claus S, Jansky M. Working relationship between primary and specialist care in analysing elevated liver values-a survey from the point of view of gastroenterologists. Wien Med Wochenschr 2021. [PMID: 34185218 DOI: 10.1007/s10354-021-00855-5] [Reference Citation Analysis]
127 Hytiroglou P, Theise ND. Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. Virchows Arch. 2018;473:15-22. [PMID: 29589101 DOI: 10.1007/s00428-018-2340-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
128 Wang H, Lai H, Hu T, Su W, Lu S, Lin C, Hung C, Chuang P, Wang J, Lee M, Chen C, Peng C. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy: Modified FIB-4 index and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2019;34:442-9. [DOI: 10.1111/jgh.14372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
129 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J;  Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589. [PMID: 32304611 DOI: 10.1111/liv.14482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
130 Fu X, Liu T, Xiong Z, Smaill BH, Stiles MK, Zhao J. Segmentation of histological images and fibrosis identification with a convolutional neural network. Comput Biol Med 2018;98:147-58. [PMID: 29793096 DOI: 10.1016/j.compbiomed.2018.05.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
131 Tong MJ, Huynh TT, Siripongsakun S, Chang PW, Tong LT, Ha YP, Mena EA, Weissman MF. Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. Hepatol Int 2015;9:567-77. [PMID: 26219830 DOI: 10.1007/s12072-015-9651-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Manne V, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol. 2014;48:e76-e84. [PMID: 24921210 DOI: 10.1097/mcg.0000000000000162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
133 Ma C, Brunt EM. Histopathologic Evaluation of Liver Biopsy for Cirrhosis. Advances in Anatomic Pathology 2012;19:220-30. [DOI: 10.1097/pap.0b013e31825c6bab] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
134 Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900-9. [PMID: 29132759 DOI: 10.1016/S2468-1253(17)30295-9] [Cited by in Crossref: 98] [Cited by in F6Publishing: 62] [Article Influence: 24.5] [Reference Citation Analysis]
135 Wu JF, Chang KC, Ni YH, Hsu HY, Chang MH. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion. J Infect Dis 2021;223:1381-9. [PMID: 32860707 DOI: 10.1093/infdis/jiaa545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract. 2011;65:866-870. [PMID: 21762311 DOI: 10.1111/j.1742-1241.2011.02719.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
137 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Chang Y, Choe WH, Sinn DH, Lee JH, Ahn SH, Lee H, Shim JJ, Jun DW, Park SY, Nam JY, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Kwon SY, Paik SW, Yoon JH. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. J Infect Dis 2017;216:1407-14. [PMID: 29029102 DOI: 10.1093/infdis/jix506] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
140 Toshikuni N, Takuma Y, Tsutsumi M. Management of gastroesophageal varices in cirrhotic patients: current status and future directions. Ann Hepatol 2016;15:314-25. [PMID: 27049485 DOI: 10.5604/16652681.1198800] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
141 Lei JH, Peng F, Chen Z, Xiao XQ. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis 2019;19:363. [PMID: 31039732 DOI: 10.1186/s12879-019-3988-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
142 Crawford JM, Bioulac-sage P, Hytiroglou P. Structure, Function, and Responses to Injury. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 1-87. [DOI: 10.1016/b978-0-7020-6697-9.00001-7] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
143 Wang YQ, Cao WJ, Gao YF, Ye J, Zou GZ. Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2018; 24(12): 1312-1320 [PMID: 29599606 DOI: 10.3748/wjg.v24.i12.1312] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
144 Chan K, Yam I, Yuen J, Yuen MF, Lai CL, Alexander GJ, Chan TK, Chan V. A comprehensive HBV array for the detection of HBV mutants and genotype. Clin Biochem 2011;44:1253-60. [PMID: 21851814 DOI: 10.1016/j.clinbiochem.2011.07.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
145 Shin SK, Kim JH, Park H, Kwon OS, Lee HJ, Yeon JE, Byun KS, Suh SJ, Yim HJ, Kim YS. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. J Gastroenterol Hepatol. 2015;30:1775-1781. [PMID: 26095700 DOI: 10.1111/jgh.13020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
146 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
147 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
148 Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2013;7:327-34. [PMID: 21688182 DOI: 10.1007/s12072-011-9282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
149 Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27:638-643. [PMID: 25831135 DOI: 10.1097/meg.0000000000000341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
150 Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med 2015;30:32-41. [PMID: 25589833 DOI: 10.3904/kjim.2015.30.1.32] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
151 Baiguera C, Boschetti A, Raffetti E, Zanini B, Puoti M, Donato F. Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial. Complement Med Res 2018;25:376-82. [PMID: 30372693 DOI: 10.1159/000484927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
152 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
153 Zhao J, Han M, Zhou L, Liang P, Wang Y, Feng S, Lu H, Yuan X, Han K, Chen X, Liu S, Cheng J. TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways. Hepatol Int 2020;14:145-60. [PMID: 31758498 DOI: 10.1007/s12072-019-09997-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. Hepatol Res. 2016;46:22-28. [PMID: 25651806 DOI: 10.1111/hepr.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
155 Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc 2021;120:1563-71. [PMID: 33334659 DOI: 10.1016/j.jfma.2020.11.019] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Wu Z, Gong Y, Peng J, Zhang X, Tang L. Correlation Between Serum Entecavir Concentration and Virological Response in Patients with Chronic Type B Hepatitis. Med Sci Monit 2019;25:6998-7004. [PMID: 31530794 DOI: 10.12659/MSM.916553] [Reference Citation Analysis]
157 Feng R, Yuan X, Shao C, Ding H, Liebe R, Weng H. Are we any closer to treating liver fibrosis (and if no, why not)? Journal of Digestive Diseases 2018;19:118-26. [DOI: 10.1111/1751-2980.12584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
158 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
159 Abo El-Khair SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, Abd-Elfattah N, Eldeek B, Farid K. Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study. J Med Virol 2020. [PMID: 32558950 DOI: 10.1002/jmv.26204] [Reference Citation Analysis]
160 Su T, Liao C, Liu C, Huang K, Tseng T, Yang H, Liu C, Chen P, Chen D, Kao J. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology 2018;288:293-9. [DOI: 10.1148/radiol.2018171116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
161 Chen J, Zhao SS, Liu XX, Huang ZB, Huang Y. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clin Ther 2017;39:1870-80. [PMID: 28797777 DOI: 10.1016/j.clinthera.2017.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
162 Kim JJ, Kim JH, Koo JK, Choi YJ, Ko SY, Choe WH, Kwon SY. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites. Clin Mol Hepatol 2014;20:47-55. [PMID: 24757658 DOI: 10.3350/cmh.2014.20.1.47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
163 Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
164 Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology 2017;67:1134-6. [DOI: 10.1016/j.jhep.2017.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
165 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
166 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
167 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
168 Wang J, Yu Y, Li G, Shen C, Meng Z, Zheng J, Jia Y, Chen S, Zhang X, Zhu M, Song Z, Wu J, Shao L, Qian P, Mao X, Wang X, Huang Y, Zhao C, Zhang J, Qiu C, Zhang W. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017;. [PMID: 28870671 DOI: 10.1016/j.jhep.2017.08.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
169 Fintha A, Gasparics Á, Rosivall L, Sebe A. Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition-An Outstanding Challenge. Front Pharmacol 2019;10:388. [PMID: 31057405 DOI: 10.3389/fphar.2019.00388] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
170 Bedossa P, Garcia-Tsao G, Jain D. Cirrhosis Regression and Subclassification. Surg Pathol Clin 2013;6:295-309. [PMID: 26838976 DOI: 10.1016/j.path.2013.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
171 Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget 2017;8:92431-41. [PMID: 29190928 DOI: 10.18632/oncotarget.21369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
172 Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Wang T, Liu H, Ou X, Wee A, Theise ND, Jia J, You H. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy. Sci Rep 2018;8:2989. [PMID: 29445243 DOI: 10.1038/s41598-018-21179-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
173 Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. Journal of Hepatology 2015;63:1118-25. [DOI: 10.1016/j.jhep.2015.06.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
174 Brouwer WP, Sonneveld MJ, Xie Q, Guo S, Zhang N, Zeuzem S, Tabak F, Zhang Q, Simon K, Akarca US, Streinu-Cercel A, Hansen BE, Janssen HL. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2016;23:419-26. [PMID: 26403919 DOI: 10.1111/jvh.12468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
175 Tsochatzis EA, Bosch J, Burroughs AK. Future treatments of cirrhosis. Expert Rev Gastroenterol Hepatol 2014;8:571-81. [PMID: 24909884 DOI: 10.1586/17474124.2014.902303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
176 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
177 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
178 Guo J, Gao XS. Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients. World J Clin Cases 2021; 9(14): 3238-3251 [PMID: 34002133 DOI: 10.12998/wjcc.v9.i14.3238] [Reference Citation Analysis]
179 Stoopen-Rometti M, Encinas-Escobar ER, Ramirez-Carmona CR, Wolpert-Barraza E, Kimura-Hayama E, Sosa-Lozano LA, Favila R, Kimura-Fujikami Y, Saavedra-Abril JA, Loaeza-Del Castillo A. Diagnosis and quantification of fibrosis, steatosis, and hepatic siderosis through multiparametric magnetic resonance imaging. Rev Gastroenterol Mex 2017;82:32-45. [PMID: 28089429 DOI: 10.1016/j.rgmx.2016.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
181 Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773-780. [PMID: 26626497 DOI: 10.1016/j.jhep.2015.11.012] [Cited by in Crossref: 143] [Cited by in F6Publishing: 135] [Article Influence: 20.4] [Reference Citation Analysis]
182 Lee SW, Kim SM, Hur W, Kang BY, Lee HL, Nam H, Yoo SH, Sung PS, Kwon JH, Jang JW, Kim SJ, Yoon SK. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. PLoS One 2021;16:e0261067. [PMID: 34879114 DOI: 10.1371/journal.pone.0261067] [Reference Citation Analysis]
183 Marzano A, Tucci A, Chialà C, Saracco GM, Fadda M, Debernardi Venon W. Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.18.02534-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Hsiao CY, Teng X, Su TH, Lee PH, Kao JH, Huang KW. Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. Clin Res Hepatol Gastroenterol 2020;44:12-20. [PMID: 31076362 DOI: 10.1016/j.clinre.2019.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
185 Ghozy S, Nam NH, Radwan I, Karimzadeh S, Tieu TM, Hashan MR, Abbas AS, Eid PS, Vuong NL, Khang NV, Elgabalawy E, Sayed AK, Hoa PTL, Huy NT. Therapeutic efficacy of hepatitis B virus vaccine in treatment of chronic HBV infections: A systematic review and meta-analysis. Rev Med Virol 2020;30:e2089. [PMID: 31811678 DOI: 10.1002/rmv.2089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
186 Chang RH, Nyamsuren T, Gyawali S, Fu SC, Huang YW, Hu RT, Yang SS. Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study. J Med Ultrasound 2017;25:161-6. [PMID: 30065482 DOI: 10.1016/j.jmu.2017.03.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Li J, Liu FW, Wu DB, Chen EQ, Chen XJ, Chen SC, Liu C, Zhao LS, Tang H, Zhou TY. TRAIL inhibits HBV replication and expression by down-regulating liver-enriched transcription factors. Arab J Gastroenterol 2020;21:169-73. [PMID: 32732169 DOI: 10.1016/j.ajg.2020.05.002] [Reference Citation Analysis]
188 Hiramatsu N, Yamada R, Takehara T. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. J Gastroenterol Hepatol. 2016;31:546-552. [PMID: 26574149 DOI: 10.1111/jgh.13229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
189 Park MS, Han K, Kim SU. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology 2014;8:501-11. [DOI: 10.1586/17474124.2014.898563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
190 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
191 Zoulim F, Bailly F, Johnson M, Kessler C. Treatment of human immunodeficiency virus and hepatitis B virus infections. Haemophilia 2012;18 Suppl 4:34-7. [PMID: 22726080 DOI: 10.1111/j.1365-2516.2012.02826.x] [Reference Citation Analysis]
192 Xie G, Wang X, Wei R, Wang J, Zhao A, Chen T, Wang Y, Zhang H, Xiao Z, Liu X, Deng Y, Wong L, Rajani C, Kwee S, Bian H, Gao X, Liu P, Jia W. Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. BMC Med 2020;18:144. [PMID: 32498677 DOI: 10.1186/s12916-020-01595-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
193 Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol 2014;2:285-91. [PMID: 26355326 DOI: 10.14218/JCTH.2014.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
194 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
195 Kim MA, Kim SU, Sinn DH, Jang JW, Lim YS, Ahn SH, Shim JJ, Seo YS, Baek YH, Kim SG, Kim YS, Kim JH, Choe WH, Yim HJ, Lee HW, Kwon JH, Lee SW, Jang JY, Kim HY, Park Y, Kim GA, Yang H, Lee HA, Koh M, Lee YS, Kim M, Chang Y, Kim YJ, Yoon JH, Zoulim F, Lee JH. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 2020;69:2214-22. [PMID: 32209606 DOI: 10.1136/gutjnl-2019-320015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
196 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
197 Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014;40:804-10. [PMID: 25109610 DOI: 10.1111/apt.12908] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
198 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol 2018;42:40-7. [PMID: 28757048 DOI: 10.1016/j.clinre.2017.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
200 Liu N, Yang N, Ma W, Yang S, Hu C, Li J, Zhao Y, Xu G, He Y. Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study. Front Med (Lausanne) 2021;8:655530. [PMID: 33898489 DOI: 10.3389/fmed.2021.655530] [Reference Citation Analysis]
201 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology 2021;160:1502-1520.e1. [PMID: 33529675 DOI: 10.1053/j.gastro.2020.09.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
203 Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int 2017;37:45-51. [DOI: 10.1111/liv.13291] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
204 Jeng WJ, Chien RN, Liaw YF. Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy. Lancet Infect Dis 2021;21:910-1. [PMID: 34174230 DOI: 10.1016/S1473-3099(21)00317-0] [Reference Citation Analysis]
205 Kapoor R, Kottilil S. Strategies to eliminate HBV infection. Future Virol 2014;9:565-85. [PMID: 25309617 DOI: 10.2217/fvl.14.36] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
206 Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HL, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020;72:1088-96. [DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
207 Park JH, Seo N, Chung YE, Kim SU, Park YN, Choi JY, Park MS, Kim MJ. Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. Eur Radiol 2021;31:4813-23. [PMID: 33439321 DOI: 10.1007/s00330-020-07600-3] [Reference Citation Analysis]
208 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 165] [Article Influence: 15.5] [Reference Citation Analysis]
209 Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, Kim HJ. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother 2015;59:5348-56. [PMID: 26100697 DOI: 10.1128/AAC.01017-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
210 Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64:667-672. [PMID: 24833635 DOI: 10.1136/gutjnl-2014-307237] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 15.9] [Reference Citation Analysis]
211 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 21.8] [Reference Citation Analysis]
212 Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Berg T, Lampertico P. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology 2018;68:1129-36. [DOI: 10.1016/j.jhep.2018.01.031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
213 Wang Q, Li H, Ding D, Peng M, Ren H, Hu P. Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. J Clin Transl Hepatol 2018;6:11-7. [PMID: 29577027 DOI: 10.14218/JCTH.2017.00020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
214 Sharma M, Radhakrishnan R. CTGF is obligatory for TGF-β1 mediated fibrosis in OSMF. Oral Oncol 2016;56:e10-1. [PMID: 27036370 DOI: 10.1016/j.oraloncology.2016.03.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
215 Jian ZW, Wu XW, Chen ZX, Wang JC, Peng JY, Lao XM. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2187-98. [PMID: 30815819 DOI: 10.1007/s10620-019-05543-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
216 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
217 Hsu L, Bowlus CL, Stewart SL, Nguyen TT, Dang J, Chan B, Chen MS. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci. 2013;58:807-814. [PMID: 23073671 DOI: 10.1007/s10620-012-2396-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 43.0] [Reference Citation Analysis]
219 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
220 Kim KH, Joo DJ, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. Dig Liver Dis 2020;52:1338-45. [PMID: 32771386 DOI: 10.1016/j.dld.2020.07.004] [Reference Citation Analysis]
221 Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat. 2013;20 Suppl 2:1-20. [PMID: 23827008 DOI: 10.1111/jvh.12120] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
222 Suk-Fong Lok A. Hepatitis B: 50 years after the discovery of Australia antigen. J Viral Hepat. 2015;Aug 17; Epub ahead of print. [PMID: 26280668 DOI: 10.1111/jvh.12444] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
223 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
224 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
225 Jin X, Fu B, Wu ZJ, Zheng XQ, Hu JH, Jin LF, Tang LL. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobiliary Pancreat Dis Int 2020;19:384-9. [PMID: 32540209 DOI: 10.1016/j.hbpd.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Wu SD, Ding H, Liu LL, Zhuang Y, Liu Y, Cheng LS, Wang SQ, Tseng YJ, Wang JY, Jiang W. Longitudinal monitoring of liver stiffness by acoustic radiation force impulse imaging in patients with chronic hepatitis B receiving entecavir. Clin Res Hepatol Gastroenterol 2018;42:227-36. [PMID: 29066092 DOI: 10.1016/j.clinre.2017.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
227 Chen SH, Peng CY, Chiang IP, Lai HC, Lee CJ, Su WP, Kao JT, Chuang PH. Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C. Medicine (Baltimore) 2016;95:e4736. [PMID: 27583917 DOI: 10.1097/MD.0000000000004736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
228 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017;67:847-861. [PMID: 28778687 DOI: 10.1016/j.jhep.2017.05.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 20.4] [Reference Citation Analysis]
229 Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol 2018;31:632-8. [PMID: 30285571 DOI: 10.1089/vim.2018.0022] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
230 Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Honda K, Seike M, Oribe J, Endo M, Arakawa M, Syo H, Iwao M, Tokoro M, Nishimura J, Mori T, Yamashita T, Fukuchi S, Muro T, Murakami K. Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy. World J Hepatol 2016; 8(13): 597-604 [PMID: 27168872 DOI: 10.4254/wjh.v8.i13.597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
232 Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1177. [PMID: 32392752 DOI: 10.3390/cancers12051177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
233 Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WMS, van Leeuwen DJ; The International Liver Pathology Study Group. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Histopathology 2016;68:953-67. [DOI: 10.1111/his.12957] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
234 Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241-1249. [PMID: 24957159 DOI: 10.1038/ajg.2014.157] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 10.0] [Reference Citation Analysis]
235 Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, Park JY, De Vuyst H, Herrero R. European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology 2015;39:S120-38. [DOI: 10.1016/j.canep.2015.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
236 Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges. Biomed Res Int 2020;2020:9609731. [PMID: 33029534 DOI: 10.1155/2020/9609731] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
238 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
240 Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol. 2013;59:880-881. [PMID: 23673137 DOI: 10.1016/j.jhep.2013.05.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
241 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
242 Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399-408. [PMID: 22806323 DOI: 10.1002/hep.25937] [Cited by in Crossref: 137] [Cited by in F6Publishing: 133] [Article Influence: 15.2] [Reference Citation Analysis]
243 Frider B, Castillo A, Gordo-gilart R, Bruno A, Amante M, Alvarez L, Mathet V. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MdR3. Annals of Hepatology 2015;14:745-51. [DOI: 10.1016/s1665-2681(19)30771-9] [Cited by in Crossref: 8] [Article Influence: 1.1] [Reference Citation Analysis]
244 Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology. 2015;61:1154-1162. [PMID: 25476749 DOI: 10.1002/hep.27630] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
245 Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Kamimura K, Yano M. Natural regression of fibrosis in chronic hepatitis B. World J Gastroenterol 2016; 22(24): 5459-5466 [PMID: 27350724 DOI: 10.3748/wjg.v22.i24.5459] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
246 Peng D, Xing HY, Li C, Wang XF, Hou M, Li B, Chen JH. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:348. [PMID: 33076834 DOI: 10.1186/s12876-020-01477-8] [Reference Citation Analysis]
247 Tsai HW, Lin YJ, Wu HC, Chang TT, Wu IC, Cheng PN, Yen CJ, Chan SH, Huang W, Su IJ. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. Oncotarget 2016;7:27724-34. [PMID: 27027237 DOI: 10.18632/oncotarget.8388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
248 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
249 Liang XE, Chen YP. Clinical Application of Vibration Controlled Transient Elastography in Patients with Chronic Hepatitis B. J Clin Transl Hepatol 2017;5:368-75. [PMID: 29226103 DOI: 10.14218/JCTH.2017.00006] [Reference Citation Analysis]
250 Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clin Liver Dis. 2019;23:401-416. [PMID: 31266616 DOI: 10.1016/j.cld.2019.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
251 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
252 Wangler J, Jansky M. [Evaluation of abnormal liver chemistries in primary care - A survey on the prerequisites, procedure and challenges faced by general practitioners]. Z Gastroenterol 2020. [PMID: 32838434 DOI: 10.1055/a-1213-6491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Magalhães-Costa P, Lebre L, Peixe P, Santos S, Chagas C. Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. GE Port J Gastroenterol 2016;23:233-42. [PMID: 28868468 DOI: 10.1016/j.jpge.2016.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
254 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 25.8] [Reference Citation Analysis]
255 Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int. 2011;31 Suppl 1:117-121. [PMID: 21205148 DOI: 10.1111/j.1478-3231.2010.02388.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
256 Tseng KC, Tseng CW, Hsieh TY, Peng CY, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC, Kao JH. Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. Hepatol Res 2016;46:642-9. [PMID: 26422680 DOI: 10.1111/hepr.12600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
257 Perrillo RP. Hepatitis B virus treatment: Which patients require immediate treatment. Clin Liver Dis (Hoboken) 2013;2:11-4. [PMID: 30992812 DOI: 10.1002/cld.140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
258 Duseja A. Reversibility of hepatic fibrosis and cirrhosis-another evidence. J Clin Exp Hepatol. 2013;3:167-168. [PMID: 25755493 DOI: 10.1016/j.jceh.2013.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
259 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. Journal of Hepatology 2012;57:1326-35. [DOI: 10.1016/j.jhep.2012.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
260 Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol. 2012;303:G498-G506. [PMID: 22700824 DOI: 10.1152/ajpgi.00525.2011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
261 Yang HY, Zheng NQ, Li DM, Gu L, Peng XM. Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Virol J 2014;11:165. [PMID: 25224377 DOI: 10.1186/1743-422X-11-165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
262 Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017;23:302-307. [PMID: 29281870 DOI: 10.3350/cmh.2017.0078] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
263 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Park J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. Gut Liver. 2017;11:828-834. [PMID: 28651305 DOI: 10.5009/gnl16484] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
265 Chen Y, Zhao Z, Fan H, Li Z, He Y, Liu C. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial. Contemp Clin Trials Commun 2020;19:100601. [PMID: 32642592 DOI: 10.1016/j.conctc.2020.100601] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
266 D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One 2016;11:e0155967. [PMID: 27304619 DOI: 10.1371/journal.pone.0155967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
267 Jang YO, Jun BG, Baik SK, Kim MY, Kwon SO. Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol. 2015;21:141-149. [PMID: 26157751 DOI: 10.3350/cmh.2015.21.2.141] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
268 Pan HY, Pan HY, Chen L, Yang DH, Huang HJ, Tong YX, Chen CR, Yan J. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. Clin Microbiol Infect 2015;21:1123.e1-9. [PMID: 26253290 DOI: 10.1016/j.cmi.2015.07.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
269 Tucker JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, Miller V, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infect Dis 2017;17:701. [PMID: 29143673 DOI: 10.1186/s12879-017-2771-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
270 Miquel M, Núñez Ó, Trapero-marugán M, Díaz-sánchez A, Jiménez M, Arenas J, Canós AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Annals of Hepatology 2013;12:205-12. [DOI: 10.1016/s1665-2681(19)31358-4] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
271 Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012;56:520-526. [PMID: 22037226 DOI: 10.1016/j.jhep.2011.09.018] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
272 Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
273 Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289-1295. [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 15.6] [Reference Citation Analysis]
274 D’Angelo S, Secondulfo M, De Cristofano R, Sorrentino P. Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma? World J Gastroenterol 2013; 19(14): 2141-2143 [PMID: 23599639 DOI: 10.3748/wjg.v19.i14.2141] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
275 Lung CC, Jian ZH, Huang JY, Nfor ON. Effect of coexisting diabetes mellitus and chronic kidney disease on mortality of cirrhotic patients with esophageal variceal bleeding. BMC Gastroenterol 2016;16:29. [PMID: 26924648 DOI: 10.1186/s12876-016-0434-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
276 Wang C, Kao J. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? Hepatology 2019;69:1843-1843. [DOI: 10.1002/hep.30532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
277 Ho MJ, Lee DR, Im SH, Yoon JA, Shin CY, Kim HJ, Jang SW, Choi YW, Han YT, Kang MJ. Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. International Journal of Pharmaceutics 2018;543:52-9. [DOI: 10.1016/j.ijpharm.2018.03.042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
278 Kose S, Tatar B, Gül S, Pala E. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. Acta Clin Belg 2016;71:244-9. [PMID: 27075801 DOI: 10.1080/17843286.2015.1118183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
280 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
281 Wong RJ, Khalili M. A Patient-Centered Hepatitis B Virus (HBV) Educational Intervention Improves HBV Care Among Underserved Safety-Net Populations. J Clin Gastroenterol 2020;54:642-7. [PMID: 31688365 DOI: 10.1097/MCG.0000000000001276] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
282 Pan CQ, Tong M, Kowdley KV, Hu K, Chang T, Lai C, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:1047-1050.e1. [DOI: 10.1016/j.cgh.2012.03.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
283 Yin L, Huang G, Lau WY, Zhou WP. Reply to Letter: "Adjuvant Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus--Related Hepatocellular Carcinoma". Ann Surg 2017;265:e47-8. [PMID: 28266989 DOI: 10.1097/SLA.0000000000001229] [Reference Citation Analysis]
284 Cosconea S, Fontaine H, Méritet JF, Corouge M, Sogni P, Vallet-Pichard A, Mallet V, Legendre C, Pol S. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol. 2012;57:55-60. [PMID: 22414762 DOI: 10.1016/j.jhep.2012.02.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
285 Chevaliez S, Dauvillier C, Dubernet F, Poveda JD, Laperche S, Hézode C, Pawlotsky JM. The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F. J Clin Microbiol 2017;55:1211-9. [PMID: 28202793 DOI: 10.1128/JCM.02219-16] [Cited by in Crossref: 10] [Article Influence: 2.0] [Reference Citation Analysis]
286 Li G, Zhang Q, Yu Y, Qiu C, Zhang H, Zhang M, Song Z, Yang Y, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Zhang W, Chen Z. Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment. J Viral Hepat 2019;26 Suppl 1:50-8. [PMID: 31380590 DOI: 10.1111/jvh.13152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
287 Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, Mchutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clinical Gastroenterology and Hepatology 2017;15:1087-1094.e2. [DOI: 10.1016/j.cgh.2017.01.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
288 Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatol Int 2016;10:294-301. [PMID: 26399763 DOI: 10.1007/s12072-015-9662-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
289 Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 2015;151:639-52. [PMID: 25962692 DOI: 10.1007/s10549-015-3382-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
290 Nguyen AP, Pham YHT, Vu GH, Nguyen MH, Hoang TN, Holterman A. Biliary atresia liver histopathological determinants of early post-Kasai outcome. J Pediatr Surg 2021;56:1169-73. [PMID: 33838902 DOI: 10.1016/j.jpedsurg.2021.03.039] [Reference Citation Analysis]
291 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
292 Boyd A, Bottero J, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Serfaty L, Lacombe K. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. J Int AIDS Soc. 2017;20:21426. [PMID: 28362068 DOI: 10.7448/ias.20.1.21426] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
293 Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol. 2013;37:559-563. [PMID: 23932705 DOI: 10.1016/j.clinre.2013.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
294 Yan L, Zhu X, Bai L, Liang L, Chen E, Du L, Wang L, Chen L, Tang H. Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy: ALT and fibroscan. Hepatology Research 2013;43:185-91. [DOI: 10.1111/j.1872-034x.2012.01068.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
295 Wang JH, Chuah SK, Lu SN, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. J Gastroenterol Hepatol. 2012;27:1213-1218. [PMID: 22432969 DOI: 10.1111/j.1440-1746.2012.07132.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
296 Xu LM, Liu P; Hepatology Committee of Chinese Association of Integrative Medicine, China. Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition). J Integr Med 2020;18:203-13. [PMID: 32331978 DOI: 10.1016/j.joim.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
297 Berardis S, Sattwika PD, Najimi M, Sokal EM. Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects. World J Gastroenterol 2015; 21(3): 742-758 [PMID: 25624709 DOI: 10.3748/wjg.v21.i3.742] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
298 Jeng W, Sheen I, Chen Y, Hsu C, Chien R, Chu C, Liaw Y. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96. [DOI: 10.1002/hep.26549] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 16.7] [Reference Citation Analysis]
299 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
300 Ha JM, Sohn W, Cho JY, Pyo JH, Choi K, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Paik YH. Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clin Mol Hepatol 2015;21:232-41. [PMID: 26523268 DOI: 10.3350/cmh.2015.21.3.232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
301 Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizabal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Annals of Hepatology 2014;13:327-36. [DOI: 10.1016/s1665-2681(19)30861-0] [Cited by in Crossref: 9] [Article Influence: 1.1] [Reference Citation Analysis]
302 Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther. 2015;42:1182-1191. [PMID: 26381928 DOI: 10.1111/apt.13409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
303 Trivella JP, Martin P, Carrion AF. Novel targeted therapies for the management of liver fibrosis. Expert Opinion on Emerging Drugs 2020;25:59-70. [DOI: 10.1080/14728214.2020.1735350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
304 Kong Y, You H, Jia J. Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. Hepatol Int 2016;10:239-41. [DOI: 10.1007/s12072-016-9714-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
305 Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. J Med Virol 2015;87:999-1007. [PMID: 25711201 DOI: 10.1002/jmv.24150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
307 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 131.1] [Reference Citation Analysis]
308 Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969. [PMID: 27446846 DOI: 10.1155/2016/5234969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
309 Wu X, Zhou J, Sun Y, Ding H, Chen G, Xie W, Piao H, Xu X, Jiang W, Ma H, Ma A, Chen Y, Xu M, Cheng J, Xu Y, Meng T, Wang B, Chen S, Shi Y, Kong Y, Ou X, You H, Jia J. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. Hepatol Int 2021;15:82-92. [PMID: 33460002 DOI: 10.1007/s12072-020-10114-1] [Reference Citation Analysis]
310 Köse Ş, Tatli Kiş T, Atalay S. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy. J Chemother 2019;31:209-13. [PMID: 30963812 DOI: 10.1080/1120009X.2019.1597420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
311 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91-100. [PMID: 21503940 DOI: 10.1002/hep.24361] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
312 Xu B, Lin L, Xu G, Zhuang Y, Guo Q, Liu Y, Wang H, Zhou X, Wu S, Bao S, Cai W, Xie Q. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:372-378. [PMID: 25167956 DOI: 10.1111/jgh.12718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
313 Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107-115. [PMID: 30450681 DOI: 10.1111/apt.15058] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
314 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
315 Yuen MF, Ahn SH, Chen DS, Chen PJ, Dusheiko GM, Hou JL, Maddrey WC, Mizokami M, Seto WK, Zoulim F, Lai CL. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. J Clin Gastroenterol 2016;50:286-94. [PMID: 26840752 DOI: 10.1097/MCG.0000000000000478] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
316 Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, Kim HR, Lee JH, Shin JW. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol 2017;23:230-8. [PMID: 28669175 DOI: 10.3350/cmh.2017.0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
317 Şahin A, Namıduru M, Balkan A, Karaoğlan İ, Gülşen MT. Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy. Saudi Med J 2018;39:999-1005. [PMID: 30284582 DOI: 10.15537/smj.2018.10.23056] [Reference Citation Analysis]
318 Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35 Suppl 1:78-81. [PMID: 25529091 DOI: 10.1111/liv.12710] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
319 Wang JS, Wang X, Liu YQ, Chen LY, Zhu YL, Gu B, Sun GZ. Taohong Qizhu Ruangan Jian reverses epithelial-mesenchymal transition via transforming growth factor beta/Smad signaling pathway. Shijie Huaren Xiaohua Zazhi 2015; 23(13): 2036-2049 [DOI: 10.11569/wcjd.v23.i13.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Lee JM, Seo YS, Kim TH, Ahn JM, Yim SY, Kim SU, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:208-14. [PMID: 27194632 DOI: 10.1111/jgh.13447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
321 Yao M, Wang L, You H, Wang J, Liao H, Yang D, Liu S, Xu Q, Chen X, Jia J, Zhao J, Lu F. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta 2019;493:92-7. [PMID: 30796901 DOI: 10.1016/j.cca.2019.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
322 Wang B, Sun Y, Zhou J, Wu X, Chen S, Wu S, Liu H, Wang T, Ou X, Jia J, You H. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. Mod Pathol. 2018;31:1567-1577. [PMID: 29785021 DOI: 10.1038/s41379-018-0059-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
323 Goyal SK, Dixit VK, Shukla SK, Ghosh J, Behera M, Tripathi M, Gupta N, Ranjan A, Jain AK. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J Gastroenterol 2015;34:286-91. [DOI: 10.1007/s12664-015-0576-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
324 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf. 2012;11:361-368. [PMID: 22233350 DOI: 10.1517/14740338.2012.653340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
325 Tseng CH, Tseng CM, Wu JL, Hsu YC, El-Serag HB. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020;35:1684-1693. [PMID: 32343431 DOI: 10.1111/jgh.15078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
326 Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040. [PMID: 21682661 DOI: 10.1517/14656566.2011.590474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
327 Seto W, Fung J, Yuen M, Lai C. Future Prevention and Treatment of Chronic Hepatitis B Infection. Journal of Clinical Gastroenterology 2012;46:725-34. [DOI: 10.1097/mcg.0b013e3182610191] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
328 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
329 Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol. 2014;61:193-195. [PMID: 24650692 DOI: 10.1016/j.jhep.2014.03.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
330 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
331 Kim JH, Kim MN, Han K, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015;35:1103-15. [DOI: 10.1111/liv.12628] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
332 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
333 Cryer AM, Imperial JC. Hepatitis B in Pregnant Women and their Infants. Clin Liver Dis 2019;23:451-62. [PMID: 31266619 DOI: 10.1016/j.cld.2019.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
334 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
335 Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014;9:e93160. [PMID: 24682088 DOI: 10.1371/journal.pone.0093160] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
336 Yang SW, Kim GH, Chung JW, Sohn HR, Lee SS, Hong S, Chung SM, Jang ES, Jeong SH, Kim JW. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy. J Gastroenterol Hepatol 2015;30:1175-82. [PMID: 25707935 DOI: 10.1111/jgh.12921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
337 Lim TS, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee J, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; The Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. J Viral Hepat 2020;27:1052-60. [DOI: 10.1111/jvh.13316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
338 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
339 Liaw Y. Impact of Therapy on the Long-Term Outcome of Chronic Hepatitis B. Clinics in Liver Disease 2013;17:413-23. [DOI: 10.1016/j.cld.2013.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
340 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
341 Bansal MB, Chamroonkul N. Antifibrotics in liver disease: are we getting closer to clinical use? Hepatol Int. 2019;13:25-39. [PMID: 30302735 DOI: 10.1007/s12072-018-9897-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
342 Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol 2017;17:39. [PMID: 28279168 DOI: 10.1186/s12876-017-0596-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
343 Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv Ther 2015;32:727-41. [PMID: 26329749 DOI: 10.1007/s12325-015-0232-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
344 Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017;51:539-47. [PMID: 28067752 DOI: 10.1097/MCG.0000000000000675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
345 Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
346 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Reference Citation Analysis]
347 Yu XP, Lin Q, Huang ZP, Chen WS, Zheng MH, Zheng YJ, Li JL, Su ZJ. Clinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report. World J Clin Cases 2021; 9(3): 714-721 [PMID: 33553413 DOI: 10.12998/wjcc.v9.i3.714] [Reference Citation Analysis]
348 Fernández-Rodríguez CM, Gutiérrez-García ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther 2014; 5(3): 175-182 [PMID: 25133046 DOI: 10.4292/wjgpt.v5.i3.175] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
349 Hiraoka A, Michitaka K, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2-year observation period. Hepatol Res 2018;48:502-8. [PMID: 29314571 DOI: 10.1111/hepr.13051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
350 Wang L, Wu Z, Wang A, Jin X, Qiu Y. Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography. Nucl Med Commun 2020;41:314-9. [PMID: 31939901 DOI: 10.1097/MNM.0000000000001156] [Reference Citation Analysis]
351 Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24:70-78. [PMID: 23928932 DOI: 10.1007/s00330-013-2978-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 12.3] [Reference Citation Analysis]
352 Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
353 El Jabbour T, McHugh KE, Patil DT, Zuo C, Koo BH, Kim S, Lee H. Histologic Lesions of Porto-Sinusoidal Vascular Disease Following Phlebotomy in Hemochromatosis. Gastroenterology Res 2020;13:32-9. [PMID: 32095171 DOI: 10.14740/gr1236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608-620. [PMID: 23701455 DOI: 10.1111/hepr.12169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
355 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
356 Rigopoulou EI, Gatselis NK, Galanis K, Lygoura V, Gabeta S, Zachou K, Dalekos GN. The changing epidemiology of hepatitis B in Greece. Ann Gastroenterol 2021;34:431-7. [PMID: 33948070 DOI: 10.20524/aog.2021.0614] [Reference Citation Analysis]
357 Lin N, Yao Z, Xu L, Xu M, Yuan L, Zhuang H, Lin Y, Xu R. Bone marrow-derived mesenchymal stem cells utilize the notch signaling pathway to induce apoptosis of hepatic stellate cells via NF-κB sensor. Biol Chem 2020;401:505-15. [PMID: 31527287 DOI: 10.1515/hsz-2019-0248] [Reference Citation Analysis]
358 Murata A, Amano N, Sato S, Tsuzura H, Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K, Genda T. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy. Int J Mol Sci 2020;21:E2051. [PMID: 32192084 DOI: 10.3390/ijms21062051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Review of Gastroenterology & Hepatology 2014;6:187-98. [DOI: 10.1586/egh.12.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
360 Friedman SL. Focus. J Hepatol 2012;57:481-3. [PMID: 22691572 DOI: 10.1016/j.jhep.2012.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
361 Huang LH, Qiu YW, Hua HY, Niu XH, Wu PF, Wu HY, Zhu HY, Yang XJ, Yao SZ, Li YG. The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. Int J Infect Dis. 2013;17:e606-e609. [PMID: 23490092 DOI: 10.1016/j.ijid.2013.01.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
362 Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
363 Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) 2016;95:e3328. [PMID: 27057911 DOI: 10.1097/MD.0000000000003328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
364 Gracia-sancho J, Marrone G, Fernández-iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol 2019;16:221-34. [DOI: 10.1038/s41575-018-0097-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 13.5] [Reference Citation Analysis]
365 Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Reference Citation Analysis]
366 Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
367 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
368 Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrob Agents Chemother 2017;61:e00725-17. [PMID: 28696237 DOI: 10.1128/AAC.00725-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
369 Abayli B, Abaylı C, Gencdal G. Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(2): 32-39 [PMID: 33815864 DOI: 10.4292/wjgpt.v12.i2.32] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
370 Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, Yuen MF. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat 2019;26:818-27. [PMID: 30895682 DOI: 10.1111/jvh.13095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
371 Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol. 2013;67:247-291. [PMID: 23886003 DOI: 10.1016/B978-0-12-405880-4.00007-X] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
372 Wei L, Hu S, Hou J, Liu G, Ren H, Duan Z, Xie Q, Fang X, Jia J. A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value Health Reg Issues 2013;2:48-56. [PMID: 29702852 DOI: 10.1016/j.vhri.2013.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
373 Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol. 2011;55:474-482. [PMID: 21241754 DOI: 10.1016/j.jhep.2011.01.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
374 Brouwer WP, van der Meer AJP, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, Ten Kate FJW, Janssen HLA, Hansen BE. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat. 2017;24:1023-1031. [PMID: 28544398 DOI: 10.1111/jvh.12727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
375 Wong RJ, Jain MK, Therapondos G, Niu B, Kshirsagar O, Thamer M. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. Am J Gastroenterol 2021;116:1465-75. [PMID: 33661148 DOI: 10.14309/ajg.0000000000001195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
377 Unal E, Idilman IS, Karçaaltıncaba M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. Expert Rev Gastroenterol Hepatol 2017;11:167-82. [PMID: 27937040 DOI: 10.1080/17474124.2017.1271710] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
378 Chang XJ, Shi YW, Wang J, Liu HB, Chen Y, Zhu XN, Chen YP, Yu ZJ, Shang QH, Tan L, Li Q, Jiang L, Xiao GM, Chen L, Lu W, Hu XY, Long QH, An LJ, Zou ZY, Wong VW, Yang YP, Fan JG. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00122-3. [PMID: 34275749 DOI: 10.1016/j.hbpd.2021.06.009] [Reference Citation Analysis]
379 Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat 2017;24:982-9. [PMID: 28414893 DOI: 10.1111/jvh.12717] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
380 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
381 Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14:513-520. [PMID: 32319045 DOI: 10.1007/s12072-020-10031-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
382 Shibayama M, Serrano-Luna J, Sohda T, Kawashima M, Yamauchi E, Tanaka T, Ueda S, Morihara D, Anan A, Takeyama Y, Irie M, Iwata K, Shakado S, Sakisaka S. Restoration of albumin production by nucleoside analogue therapy in patients with chronic hepatitis B. Med Mol Morphol 2014;47:207-12. [PMID: 24326379 DOI: 10.1007/s00795-013-0065-5] [Reference Citation Analysis]
383 Kim JH, Jung SW, Byun SS, Shin JW, Park BR, Kim MH, Kim CJ, Park NH. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. Int J Clin Pharm. 2015;37:1228-1234. [PMID: 26364195 DOI: 10.1007/s11096-015-0193-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
384 Matsuzaki K, Seki T, Okazaki K. TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49:971-81. [PMID: 24263677 DOI: 10.1007/s00535-013-0910-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
385 Lüllau A, Petroff D, Bätz O, Kramer J, Jedrysiak K, Tenckhoff H, Berg T, Wolffram I, Wiegand J. Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur J Gastroenterol Hepatol 2018;30:280-3. [PMID: 29324587 DOI: 10.1097/MEG.0000000000001052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
386 Chang SW, Fann CS, Su WH, Wang YC, Weng CC, Yu CJ, Hsu CL, Hsieh AR, Chien RN, Chu CM. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS One. 2014;9:e99724. [PMID: 24940741 DOI: 10.1371/journal.pone.0099724] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
387 Society for Maternal-Fetal Medicine (SMFM). Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214:6-14. [PMID: 26454123 DOI: 10.1016/j.ajog.2015.09.100] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 13.3] [Reference Citation Analysis]
388 Saab S, Song D, Challita YP, Xiwen Zhou T, Saab EG, Viramontes MR, Choi G, Durazo FA, Han SB, El Kabany MM, Jackson NJ, Busuttil RW. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. Clin Transplant 2019;33:e13740. [PMID: 31651048 DOI: 10.1111/ctr.13740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
389 Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011;11:52. [PMID: 21261993 DOI: 10.1186/1471-2458-11-52] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
390 Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. J Clin Transl Hepatol 2020;8:377-84. [PMID: 33447520 DOI: 10.14218/JCTH.2020.00039] [Reference Citation Analysis]
391 Xie YD, Ma H, Feng B, Wei L. Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chin Med J (Engl) 2017;130:2190-7. [PMID: 28875955 DOI: 10.4103/0366-6999.213969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
392 Ratnam D, Angus P. Global Perspectives: Australia – Real World Experience with HBV Antiviral Therapy. Curr Hepatitis Rep 2012;11:213-20. [DOI: 10.1007/s11901-012-0152-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: From fiction to reality. Best Practice & Research Clinical Gastroenterology 2017;31:129-41. [DOI: 10.1016/j.bpg.2017.04.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 13.4] [Reference Citation Analysis]
394 Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015;62:56-63. [PMID: 25176615 DOI: 10.1016/j.jhep.2014.08.031] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
395 Wang Y, Liang X, Yang J, Wang H, Tan D, Chen S, Cheng J, Chen Y, Sun J, Rong F, Yang W, Liu H, Liu Z, Zheng Y, Liang J, Li S, Liu Z, Hou J. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat 2018;25:598-607. [PMID: 29193542 DOI: 10.1111/jvh.12835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
396 Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013;19:887-895. [PMID: 23788462 DOI: 10.1002/lt.23690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
397 Cornberg M, Höner Zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut 2014;63:1208-9. [PMID: 24398879 DOI: 10.1136/gutjnl-2013-306221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
398 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
399 Xu JH, Wang S, Xu ZN, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144. J Viral Hepat 2017;24:877-84. [PMID: 28345157 DOI: 10.1111/jvh.12710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
400 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother. 2013;57:3369-3374. [PMID: 23650172 DOI: 10.1128/aac.00587-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Tseng T, Liu C, Su T, Yang H, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases 2012;206:1521-31. [DOI: 10.1093/infdis/jis569] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
402 Wang X, Wang Z, Chi X, Wu R, Jin Q, Xu H, Gao X, Yu L, Chen Y, Shang J, Liu L, Zhang S, Jiang Y, Zhang M, Tong Q, Zhang L, Tan Y, Ma A, Dang S, Xu B, Jin Z, Li J, Li X, Lu F, Niu J. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int J Infect Dis 2020;99:171-8. [PMID: 32721532 DOI: 10.1016/j.ijid.2020.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
403 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
404 Leung TM, Wang X, Kitamura N, Fiel MI, Nieto N. Osteopontin delays resolution of liver fibrosis. Lab Invest. 2013;93:1082-1089. [PMID: 23999249 DOI: 10.1038/labinvest.2013.104] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
405 Kubo S, Takemura S, Tanaka S, Shinkawa H, Nishioka T, Nozawa A, Kinoshita M, Hamano G, Ito T, Urata Y. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21(27): 8249-8255 [PMID: 26217076 DOI: 10.3748/wjg.v21.i27.8249] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
406 Yuan H, Lee WM. Update of chronic hepatitis B. Curr Opin Gastroenterol. 2011;27:217-223. [PMID: 21423004 DOI: 10.1097/MOG.0b013e32834595b5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
407 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
408 Hara Y, Tokodai K, Nakanishi C, Miyagi S, Kawagishi N. Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report. Surg Case Rep. 2016;2:118. [PMID: 27797067 DOI: 10.1186/s40792-016-0246-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
409 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
410 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Ho C, Chien R, Cheng P, Liu J, Liu C, Su C, Wu I, Li I, Tsai H, Wu S, Liu W, Chen S, Chang T. Aberrant Serum Immunoglobulin G Glycosylation in Chronic Hepatitis B Is Associated With Histological Liver Damage and Reversible by Antiviral Therapy. J Infect Dis 2014;211:115-24. [DOI: 10.1093/infdis/jiu388] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
412 Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522 [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
413 Abdelgawad IA. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients. J Clin Pathol 2015;68:154-60. [PMID: 25430496 DOI: 10.1136/jclinpath-2014-202462] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
414 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 181] [Cited by in F6Publishing: 78] [Article Influence: 16.5] [Reference Citation Analysis]
415 Yip TC, Wong GL, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. Journal of Hepatology 2019;70:361-70. [DOI: 10.1016/j.jhep.2018.10.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 21.3] [Reference Citation Analysis]
416 Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for Fibrotic Diseases: Nearing the Starting Line. Science Translational Medicine 2013;5:167sr1-167sr1. [DOI: 10.1126/scitranslmed.3004700] [Cited by in Crossref: 402] [Cited by in F6Publishing: 401] [Article Influence: 44.7] [Reference Citation Analysis]
417 Wang X, Zhang C, Zhu Y, Xiong Y, Wang Y. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. Antiviral Research 2014;103:71-7. [DOI: 10.1016/j.antiviral.2014.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
418 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
419 Wong GL. Who will have the best response to entecavir? J Gastroenterol Hepatol 2013;28:5-7. [DOI: 10.1111/jgh.12009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
420 Xie J, Han Y, Qiu Z, Li Y, Li Y, Song X, Wang H, Thio CL, Li T. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study. J Int AIDS Soc 2016;19:20659. [PMID: 26979535 DOI: 10.7448/IAS.19.1.20659] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
421 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 12.9] [Reference Citation Analysis]
422 Lotersztajn S, Mallat A. Hepatic Stellate Cells as Target for Reversal of Fibrosis/Cirrhosis. Stellate Cells in Health and Disease. Elsevier; 2015. pp. 175-84. [DOI: 10.1016/b978-0-12-800134-9.00011-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
423 Zhu H, He C, Zhao H, Jiang W, Xu S, Li J, Ma T, Huang C. Sennoside A prevents liver fibrosis by binding DNMT1 and suppressing DNMT1-mediated PTEN hypermethylation in HSC activation and proliferation. FASEB J 2020;34:14558-71. [PMID: 32946656 DOI: 10.1096/fj.202000494RR] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
424 Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist 2019;12:745-57. [PMID: 31015765 DOI: 10.2147/IDR.S185120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
425 Block TM, Alter HJ, London WT, Bray M. A historical perspective on the discovery and elucidation of the hepatitis B virus. Antiviral Res. 2016;131:109-123. [PMID: 27107897 DOI: 10.1016/j.antiviral.2016.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
426 Barone M, Shahini E, Di Leo A. Letter: can transient elastography and body mass index predict fibrosis regression in HBV patients on long-term nucleoside therapy? Aliment Pharmacol Ther 2017;45:765-6. [PMID: 28150458 DOI: 10.1111/apt.13930] [Reference Citation Analysis]
427 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
428 Iimuro Y, Yada A, Okada T, Nakamura I, Suzumura K, Xu J, Sudo M, Nishiguchi S, Kawada N, Hatano E, Fujimoto J. Cytoglobin-expressing cells in the splenic cords contribute to splenic fibrosis in cirrhotic patients. Histol Histopathol 2020;35:1319-28. [PMID: 32945524 DOI: 10.14670/HH-18-257] [Reference Citation Analysis]
429 Seto W, Cheung K, Wong DK, Huang F, Fung J, Liu KS, Lai C, Yuen M. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol 2016;51:487-95. [DOI: 10.1007/s00535-015-1128-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
430 Qiu T, Wang H, Song J, Ling W, Shi Y, Guo G, Luo Y. Assessment of liver fibrosis by ultrasound elastography and contrast-enhanced ultrasound: a randomized prospective animal study. Exp Anim 2018;67:117-26. [PMID: 29081454 DOI: 10.1538/expanim.17-0098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
431 Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66:2715-2725. [PMID: 21965435 DOI: 10.1093/jac/dkr388] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 10.6] [Reference Citation Analysis]
432 Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? Clin Mol Hepatol 2014;20:355-60. [PMID: 25548741 DOI: 10.3350/cmh.2014.20.4.355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
433 Yim SY, Seo YS, Jung CH, Kim TH, Lee JM, Kim ES, Keum B, Jong YK, An H, Kim JH, Yim HJ, Kim DS, Jeen YT, Yeon JE, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS. The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years? Liver Int. 2016;36:445-453. [PMID: 26352789 DOI: 10.1111/liv.12960] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
434 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
435 Chiang H, Lee C, Hu T, Hung C, Wang J, Lu S, Lai H, Su W, Lin C, Peng C, Chen C. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int 2018;38:1997-2005. [DOI: 10.1111/liv.13889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
436 Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology 2016;50:169-74. [DOI: 10.1097/mcg.0000000000000345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
437 Malespin M, Wong S, Siqueira F, Luc B, Ravaee B, Vainder C, Cotler SJ. Barriers to treatment of hepatitis B in an urban Chinatown community. J Clin Gastroenterol. 2012;46:e66-e70. [PMID: 22460162 DOI: 10.1097/mcg.0b013e31824e159c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
438 Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, Scott J, Lo YR, Tucker JD. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis 2016;16:1409-22. [PMID: 27615026 DOI: 10.1016/S1473-3099(16)30208-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
439 Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, Kim JW. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir. Korean J Intern Med 2015;30:170-6. [PMID: 25750558 DOI: 10.3904/kjim.2015.30.2.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
440 Lee M, Keeffe EB. Hepatitis B: modern end points of treatment and the specter of viral resistance. Gastroenterol Clin North Am. 2011;40:495-505. [PMID: 21893270 DOI: 10.1016/j.gtc.2011.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
441 Dore GJ, Danta M, Matthews GV. Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding. Lancet Gastroenterol Hepatol 2020;5:1028-9. [PMID: 33007227 DOI: 10.1016/S2468-1253(20)30270-3] [Reference Citation Analysis]
442 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
443 Lam YF, Seto WK, Wong D, Cheung KS, Fung J, Mak LY, Yuen J, Chong CK, Lai CL, Yuen MF. Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. Clin Transl Gastroenterol 2017;8:e125. [PMID: 29072673 DOI: 10.1038/ctg.2017.51] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
444 Meng T, Shi X, Gong X, Deng H, Huang Y, Shan X, Shan Y, Huang A, Long Q. Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). J Glob Antimicrob Resist 2017;8:74-81. [PMID: 28017671 DOI: 10.1016/j.jgar.2016.10.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
445 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
446 Chen SH, Li YF, Lai HC, Kao JT, Peng CY, Chuang PH, Su WP, Chiang IP. Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C. J Viral Hepat. 2012;19:654-663. [PMID: 22863270 DOI: 10.1111/j.1365-2893.2012.01588.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
447 Lo GH. Did Statins Really Reduce the Risk of Cirrhosis and Decompensation in Chronic Hepatitis B Patients? Am J Gastroenterol 2017;112:386-7. [PMID: 28154383 DOI: 10.1038/ajg.2016.486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
448 Wang B, Sun Y, Zhou J, Wu X, Chen S, Shi Y, Wu S, Liu H, Ren Y, Ou X, Jia J, You H. SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. Hepatol Int 2019;13:501-9. [PMID: 31187402 DOI: 10.1007/s12072-019-09955-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
449 Kim TH, Um SH, Lee YS, Yim SY, Jung YK, Seo YS, Kim JH, An H, Yim HJ, Yeon JE, Byun KS. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther 2022;55:83-96. [PMID: 34662436 DOI: 10.1111/apt.16658] [Reference Citation Analysis]
450 Höner Zu Siederdissen C, Cornberg M. Management of HBV and HBV/HDV-Associated Liver Cirrhosis. Visc Med 2016;32:86-94. [PMID: 27413725 DOI: 10.1159/000445518] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
451 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547. [PMID: 23389810 DOI: 10.1002/hep.26301] [Cited by in Crossref: 295] [Cited by in F6Publishing: 283] [Article Influence: 32.8] [Reference Citation Analysis]
452 Calvaruso V, Craxì A. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:219-230. [PMID: 21497740 DOI: 10.1016/j.bpg.2011.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
453 Wang ZY, Tao QF, Wang ZH, Lin KY, Huang G, Yang Y, Zhou WP, Lau WY. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study. Am J Surg 2020;219:717-25. [PMID: 31266631 DOI: 10.1016/j.amjsurg.2019.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
454 Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013;33:116-24. [DOI: 10.1111/liv.12069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
455 Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013;8:e57900. [PMID: 23536775 DOI: 10.1371/journal.pone.0057900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
456 Wang L, Chen H, Fan C, Gong Z. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection: Telbivudine Therapy in Liver Failure. J Med Virol 2013;85:1907-12. [DOI: 10.1002/jmv.23689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
457 Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 2013;56:1695-1703. [PMID: 23449268 DOI: 10.1093/cid/cit121] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
458 Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
459 Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68:2154-2163. [PMID: 23620466 DOI: 10.1093/jac/dkt147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
460 Kim JK, Ma DW, Lee KS, Paik YH. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. J Korean Med Sci 2014;29:570-5. [PMID: 24753706 DOI: 10.3346/jkms.2014.29.4.570] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
461 Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303-1310. [PMID: 24170683 DOI: 10.1002/hep.26910] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
462 Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013; 19(40): 6849-6856 [PMID: 24187460 DOI: 10.3748/wjg.v19.i40.6849] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
463 Udompap P, Kim WR. Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. Clin Liver Dis (Hoboken) 2020;15:85-90. [PMID: 32226623 DOI: 10.1002/cld.904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
464 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
465 Koksal AR, Alkim H, Boga S, Ergun M, Bayram M, Ozguven BY, Alkim C. Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better? Am J Ther. 2016;23:e429-e438. [PMID: 25650531 DOI: 10.1097/mjt.0000000000000203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
466 Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;34 Suppl 1:85-90. [PMID: 24373083 DOI: 10.1111/liv.12395] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
467 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
468 Ozaras R, Khodor H, Yetim N, Unal UK, Demirhan YE, Gultekin G, Isal B. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015;13:1457-68. [PMID: 26414781 DOI: 10.1586/14787210.2015.1093934] [Reference Citation Analysis]
469 Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Chang PE, Goh GBB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 91-106 [PMID: 26855815 DOI: 10.4292/wjgpt.v7.i1.91] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
471 Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int 2018;12:44-55. [PMID: 28361299 DOI: 10.1007/s12072-017-9795-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
472 Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29:1028-1034. [PMID: 24325451 DOI: 10.1111/jgh.12476] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
473 Lee JI, Lee HW, Kim SU, Ahn SH, Lee KS. Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. Cancers (Basel) 2019;11:E425. [PMID: 30934621 DOI: 10.3390/cancers11030425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
474 Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O, Chen T, Bopp T, Schild H, Brombacher F, Crosby JR, McCaleb ML, Waisman A, Bockamp E, Schuppan D. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. EBioMedicine 2018;29:92-103. [PMID: 29463471 DOI: 10.1016/j.ebiom.2018.01.028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
475 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
476 Ji D, Chen Y, Shang Q, Liu H, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Hu X, Wang X, Chen D, Li Z, Dong Z, Chen G, Yang Y. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. Am J Gastroenterol 2021. [PMID: 33840727 DOI: 10.14309/ajg.0000000000001239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 2017;11:999-1008. [PMID: 28965428 DOI: 10.1080/17474124.2017.1386554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
478 Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials 2021;22:701. [PMID: 34649610 DOI: 10.1186/s13063-021-05650-6] [Reference Citation Analysis]
479 Seto WK, Lau EH, Wu JT, Hung IF, Leung WK, Cheung KS, Fung J, Lai CL, Yuen MF. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. Aliment Pharmacol Ther. 2017;45:501-509. [PMID: 27976416 DOI: 10.1111/apt.13895] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
480 Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int 2014;8:478-92. [PMID: 25298848 DOI: 10.1007/s12072-014-9562-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
481 Bang SJ, Kim BG, Shin JW, Ju HU, Park BR, Kim MH, Kim CJ, Park JH, Jeong ID, Jung SW. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis. 2013;45:600-605. [PMID: 23333665 DOI: 10.1016/j.dld.2012.12.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
482 Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Amano K, Kawaguchi T, Kuromatsu R, Kawaguchi A, Miyajima I, Ide T, Kakuma T, Sata M. Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. Mol Clin Oncol 2014;2:927-34. [PMID: 25279176 DOI: 10.3892/mco.2014.398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
484 Hsu Y, Wu C, Lane H, Chang C, Tai C, Tseng C, Lo G, Perng D, Lin J, Mo L. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B. Journal of Antimicrobial Chemotherapy 2014;69:1920-7. [DOI: 10.1093/jac/dku041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
485 Minami T, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K. Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma: Comparison between HBV- and HCV- related HCC. Hepatol Res 2015;45:E99-E107. [DOI: 10.1111/hepr.12468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
486 Howell J, Balderson G, Hellard M, Gow P, Strasser S, Stuart K, Wigg A, Jeffrey G, Gane E, Angus PW. The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand: Increasing burden of preventable liver disease. Journal of Gastroenterology and Hepatology 2016;31:434-41. [DOI: 10.1111/jgh.13082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
487 Shu Z, He W, Shahen M, Guo Z, Shu J, Wu T, Bian X, Shar AH, Farag MR, Alagawany M, Liu C. Clarifying of the potential mechanism of Sinisan formula for treatment of chronic hepatitis by systems pharmacology method. Biomed Pharmacother 2018;100:532-50. [PMID: 29482047 DOI: 10.1016/j.biopha.2018.02.047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
488 Wang PC, Wei TY, Tseng TC, Lin HH, Wang CC. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. Eur J Gastroenterol Hepatol 2017;29:946-50. [PMID: 28538267 DOI: 10.1097/MEG.0000000000000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
489 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 2020;50:892-923. [PMID: 32343469 DOI: 10.1111/hepr.13504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
490 Shi Y, Guo Q, Xia F, Sun J, Gao Y. Short- and midterm repeatability of magnetic resonance elastography in healthy volunteers at 3.0 T. Magn Reson Imaging. 2014;32:665-670. [PMID: 24650683 DOI: 10.1016/j.mri.2014.02.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
491 Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912-923. [PMID: 23573915 DOI: 10.1111/jgh.12213] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
492 Ho CH, Chang TT, Chien RN. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis. PLoS One 2019;14:e0225482. [PMID: 31770396 DOI: 10.1371/journal.pone.0225482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
493 Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, Ghanekar A, Mcgilvray ID, Selzner M, Greig PD, Bhat M, Selzner N, Grant DR, Lilly LB, Renner EL. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int 2017;30:1140-9. [DOI: 10.1111/tri.13008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
494 Grizzi F. On the reversal of liver cirrhosis: mystery or reality? Clin Exp Pharmacol Physiol 2012;39:401-3. [PMID: 22524857 DOI: 10.1111/j.1440-1681.2012.05698.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
495 Sun Y, Zhang Y, Xu Y, Shu M, Bonroy K, Qiu H, Cai W. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. Epidemiol Infect 2019;147:e193. [PMID: 31364558 DOI: 10.1017/S0950268819000815] [Reference Citation Analysis]
496 Wi CI, Kim WR, Gross JB, Stadheim LM, Poterucha JJ. Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. Gut Liver 2016;10:611-6. [PMID: 26190580 DOI: 10.5009/gnl14256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
497 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002] [Cited by in Crossref: 247] [Cited by in F6Publishing: 243] [Article Influence: 35.3] [Reference Citation Analysis]
498 Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84-89. [PMID: 29427500 DOI: 10.1111/liv.13641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
499 Orr C, Myers R, Li B, Jiang Z, Flaherty J, Gaggar A, Meissner EG. Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. Liver Int 2020;40:1693-700. [PMID: 32301252 DOI: 10.1111/liv.14474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
500 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020;73:1037-45. [PMID: 32553667 DOI: 10.1016/j.jhep.2020.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
501 Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2020;158:215-225.e6. [PMID: 31574268 DOI: 10.1053/j.gastro.2019.09.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 21.3] [Reference Citation Analysis]
502 Wong GL, Kwok R, Chan HL, Tang SP, Lee E, Lam TC, Lau TW, Ma TM, Wong BC, Wong VW. Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. J Dig Dis. 2016;17:538-546. [PMID: 27185358 DOI: 10.1111/1751-2980.12359] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
503 Cheng K, Chen Y, Wang X, Xu M, Liao W, Duan X, Zhao X, Sun Y, Duan Z, Wang L. Entecavir combined with interferon-α is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Cancer 2021. [PMID: 34623636 DOI: 10.1002/cncr.33949] [Reference Citation Analysis]
504 Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. Gut. 2015;64:139-147. [PMID: 24555998 DOI: 10.1136/gutjnl-2013-305707] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 7.8] [Reference Citation Analysis]
505 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
506 Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, Liu H, Wang T, Zhao X, Wu S, Kong Y, Ou X, Wee A, Theise ND, Qiu C, Zhang W, Lu F, Jia J, You H. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clin Gastroenterol Hepatol. 2020;18:2582-2591.e6. [PMID: 32147592 DOI: 10.1016/j.cgh.2020.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
507 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
508 Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, Cosgrove D, Dietrich CF, Amy D, Bamber JC, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-rust M, Hall TJ, Nakashima K, Nightingale KR, Palmeri ML, Schafer F, Shiina T, Suzuki S, Kudo M. WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver. Ultrasound in Medicine & Biology 2015;41:1161-79. [DOI: 10.1016/j.ultrasmedbio.2015.03.007] [Cited by in Crossref: 344] [Cited by in F6Publishing: 291] [Article Influence: 49.1] [Reference Citation Analysis]
509 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
510 Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2017;45:115-126. [PMID: 27790729 DOI: 10.1111/apt.13823] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
511 Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109:1223-1233. [PMID: 24890440 DOI: 10.1038/ajg.2014.145] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
512 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2070] [Article Influence: 216.7] [Reference Citation Analysis]
513 Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 2014;20:2854-72. [PMID: 24040957 DOI: 10.1089/ars.2013.5619] [Cited by in Crossref: 133] [Cited by in F6Publishing: 118] [Article Influence: 16.6] [Reference Citation Analysis]
514 Wei L, Kao JH. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Curr Med Res Opin 2017;33:495-504. [PMID: 27882776 DOI: 10.1080/03007995.2016.1264932] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
515 Ridruejo E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? Expert Opin Drug Saf 2015;14:439-51. [PMID: 25547687 DOI: 10.1517/14740338.2015.998649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
516 Stift J, Semmler G, Wöran K, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Pinter M, Stättermayer AF, Meischl T, Beer A, Trauner M, Mandorfer M, Reiberger T. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Dig Liver Dis 2020;52:1473-9. [PMID: 32928675 DOI: 10.1016/j.dld.2020.08.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
517 Xu K, Liu LM, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, Zhang JJ. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action 2018;11:1433987. [PMID: 29447614 DOI: 10.1080/16549716.2018.1433987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
518 Li ZX, Zhao ZM, Liu P, Zheng QS, Liu CH. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet () and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial. Chin J Integr Med 2021;27:509-13. [PMID: 32572776 DOI: 10.1007/s11655-020-3257-6] [Reference Citation Analysis]
519 Jiao J, Sastre D, Fiel MI, Lee UE, Ghiassi-Nejad Z, Ginhoux F, Vivier E, Friedman SL, Merad M, Aloman C. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology. 2012;55:244-255. [PMID: 21898476 DOI: 10.1002/hep.24621] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
520 Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol 2018;53:883-9. [PMID: 29288305 DOI: 10.1007/s00535-017-1424-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
521 Theise ND, Jia J, Sun Y, Wee A, You H. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol. 2018;31:1191-1200. [PMID: 29700417 DOI: 10.1038/s41379-018-0048-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
522 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. [PMID: 23323209 DOI: 10.1038/srep01065] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 23.9] [Reference Citation Analysis]
524 Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29:1699-1705. [PMID: 24730702 DOI: 10.1111/jgh.12612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
525 Jiang X, Xie L, Huang C, Liu Y, Liu H, Liu B, Zheng L. Oral oxymatrine for hepatitis B cirrhosis: A systematic review protocol. Medicine (Baltimore) 2018;97:e13482. [PMID: 30544440 DOI: 10.1097/MD.0000000000013482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
526 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941-2947. [PMID: 22430972 DOI: 10.1128/aac.00338-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
527 Wei R, Liu H, Chen R, Sheng Y, Liu T. Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway. Exp Ther Med 2019;17:393-7. [PMID: 30651810 DOI: 10.3892/etm.2018.6966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
528 Rizzetto M. Treatment of hepatitis B virus cirrhosis. Hepat Mon 2012;12:309-11. [PMID: 22783340 DOI: 10.5812/hepatmon.6113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
529 Li JJ, Jiang HC, Wang A, Bu FT, Jia PC, Zhu S, Zhu L, Huang C, Li J. Hesperetin derivative-16 attenuates CCl4-induced inflammation and liver fibrosis by activating AMPK/SIRT3 pathway. Eur J Pharmacol 2022;915:174530. [PMID: 34902361 DOI: 10.1016/j.ejphar.2021.174530] [Reference Citation Analysis]
530 Petersen J, Buti M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol. 2012;6:683-693; quiz 694. [PMID: 23237254 DOI: 10.1586/egh.12.52] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
531 Chon YE, Park JY, Myoung S, Jung KS, Kim BK, Kim SU, Kim DY, Ahn SH, Han K. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. American Journal of Gastroenterology 2017;112:882-91. [DOI: 10.1038/ajg.2017.93] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
532 Xu HW, Lu SN, Hung CH, Chang KC, Hu TH, Wang JH. Liver stiffness measurement in cirrhotic patient -- implications of disease activity and treatment efficacy. Kaohsiung J Med Sci 2012;28:641-8. [PMID: 23217355 DOI: 10.1016/j.kjms.2012.04.032] [Reference Citation Analysis]
533 Park CH, Kim HY, Lee SW, Song do S, Song MJ, Kwon JH, You CR, Jang JW, Kim CW, Choi SW, Bae SH, Choi JY, Yoon SK. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2016;28:1179-87. [PMID: 27428552 DOI: 10.1097/MEG.0000000000000691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
534 Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol. 2012;27:662-669. [PMID: 22098452 DOI: 10.1111/j.1440-1746.2011.06971.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
535 Brahmania M, Brouwer WP, Hansen T, Mazzulli T, Feld J, Wong D, Kowgier M, Janssen HL. Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues. J Viral Hepat 2016;23:1003-8. [PMID: 27502526 DOI: 10.1111/jvh.12579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
536 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
537 Li X, Gao F, Liu H, Zhang H, Liu Y, Ye X, Geng M, Sun L, Wang R, Li Y. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score. Eur J Gastroenterol Hepatol. 2017;29:1-9. [PMID: 27749778 DOI: 10.1097/meg.0000000000000750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
538 Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377-86. [PMID: 22571899 DOI: 10.1111/j.1365-2893.2012.01602.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 8.4] [Reference Citation Analysis]
539 Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. Liver Int 2015;35:860-9. [DOI: 10.1111/liv.12605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
540 Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim H. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int 2017;37:879-87. [DOI: 10.1111/liv.13341] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
541 Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T, Inoue T, Ishii K, Kudo M. Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver: Comparison Between T1 Map and FibroScan. J Magn Reson Imaging 2015;41:329-38. [DOI: 10.1002/jmri.24529] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
542 Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014; 20(16): 4745-4752 [PMID: 24782628 DOI: 10.3748/wjg.v20.i16.4745] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
543 Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, Park NH. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol 2018;113:998-1008. [PMID: 29880971 DOI: 10.1038/s41395-018-0093-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
544 Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, Tak WY, Park SY, Kim BK. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol 2021. [PMID: 34478195 DOI: 10.1111/jgh.15678] [Reference Citation Analysis]
545 Yo IK, Kwon OS, Park JW, Lee JJ, Lee JH, Won IS, Na SY, Jang PK, Park PH, Choi DJ, Kim YS, Kim JH. The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. Clin Mol Hepatol 2015;21:32-40. [PMID: 25834800 DOI: 10.3350/cmh.2015.21.1.32] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
546 Du X, Wang J, Shao L, Hu X, Yang C, Shen L, Weng X, Zhang W. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepat. 2013;20:328-335. [PMID: 23565615 DOI: 10.1111/jvh.12034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
547 Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014;63:996-1004. [PMID: 23979965 DOI: 10.1136/gutjnl-2013-305138] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
548 Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, Wang X, Shimakami T, Okada H, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis. 2016;213:1096-1106. [PMID: 26621908 DOI: 10.1093/infdis/jiv572] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
549 Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
550 Kim MN, Han KH, Ahn SH. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316-328. [PMID: 25843736 DOI: 10.1053/j.seminoncol.2014.12.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
551 Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015;61:1512-22. [PMID: 25348661 DOI: 10.1002/hep.27586] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 17.0] [Reference Citation Analysis]
552 Hsiang JC, Bai WW, Raos Z, Stableforth W, Upton A, Selvaratnam S, Gane EJ, Gerred SJ. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand: Cirrhosis outcomes in New Zealand. Intern Med J 2015;45:160-9. [DOI: 10.1111/imj.12624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
553 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
554 Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397-411. [PMID: 28487545 DOI: 10.1038/nrgastro.2017.38] [Cited by in Crossref: 770] [Cited by in F6Publishing: 749] [Article Influence: 154.0] [Reference Citation Analysis]
555 D'Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, Bedossa P, Colombo M. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59:251-256. [PMID: 23528378 DOI: 10.1016/j.jhep.2013.03.013] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 10.4] [Reference Citation Analysis]
556 Heo J, Ahn SH, Kweon YO, Kim BH, Chan HL, Horban A, Wongcharatrawee S, Llamoso C, Lee KS. Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1485-93. [PMID: 25587617 DOI: 10.1111/jgh.12567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
557 Viganò M, Invernizzi F, Lampertico P. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? Liver Int 2015;35:107-13. [DOI: 10.1111/liv.12717] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
558 Sadler MD, Coffin CS, Lee SS. Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother. 2013;14:1363-1369. [PMID: 23557465 DOI: 10.1517/14656566.2013.786701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
559 Ortonne V, Wlassow M, Bouvier-Alias M, Melica G, Poveda JD, Laperche S, Pawlotsky JM, Chevaliez S. Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System. Microorganisms 2021;9:573. [PMID: 33799562 DOI: 10.3390/microorganisms9030573] [Reference Citation Analysis]
560 Stene-Johansen K, Yaqoob N, Overbo J, Aberra H, Desalegn H, Berhe N, Johannessen A. Dry Blood Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. PLoS One 2016;11:e0166201. [PMID: 27820845 DOI: 10.1371/journal.pone.0166201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
561 Jung HJ, Ho MJ, Ahn S, Han YT, Kang MJ. Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption. Molecules 2018;23:E731. [PMID: 29565327 DOI: 10.3390/molecules23040731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
562 Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012;23:317-22.e1. [PMID: 22265248 DOI: 10.1016/j.jvir.2011.11.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
563 Fung J, Lai CL, Seto WK, Yuen MF. The use of transient elastography in the management of chronic hepatitis B. Hepatol Int. 2011;5:868-875. [PMID: 21695588 DOI: 10.1007/s12072-011-9288-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
564 Hong Y, Shi Y, Liao W, Klahr N, Xia F, Xu C, Li Y, Guo Q. Relative ADC measurement for liver fibrosis diagnosis in chronic hepatitis B using spleen/renal cortex as the reference organs at 3 T. Clinical Radiology 2014;69:581-8. [DOI: 10.1016/j.crad.2014.01.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
565 Liu T, Wang P, Cong M, Zhang D, Liu L, Li H, Zhai Q, Li Z, Jia J, You H. Matrix metalloproteinase-1 induction by diethyldithiocarbamate is regulated via Akt and ERK/miR222/ETS-1 pathways in hepatic stellate cells. Biosci Rep 2016;36:e00371. [PMID: 27412967 DOI: 10.1042/BSR20160111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
566 Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285. [PMID: 29551708 DOI: 10.1016/j.jhep.2018.02.032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
567 Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci. 2013;58:815-823. [PMID: 23053891 DOI: 10.1007/s10620-012-2414-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
568 Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. The Lancet Gastroenterology & Hepatology 2016;1:328-40. [DOI: 10.1016/s2468-1253(16)30110-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
569 Oliveira-junior MC, Monteiro AS, Leal-junior ECP, Munin E, Osório RAL, Ribeiro W, Vieira RP. Low-level Laser Therapy Ameliorates CCl 4 -induced Liver Cirrhosis in Rats. Photochem Photobiol 2013;89:173-8. [DOI: 10.1111/j.1751-1097.2012.01211.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
570 Chon YE, Jung KS, Ha Y, Kim MN, Lee JH, Hwang SG, Ahn SH, Kim DY, Han KH, Park JY. High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. J Viral Hepat 2020;27:1119-26. [PMID: 32558181 DOI: 10.1111/jvh.13345] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
571 Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol 2017;23:170-8. [PMID: 28506056 DOI: 10.3350/cmh.2016.0086] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
572 Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015;60:260-268. [PMID: 25179493 DOI: 10.1007/s10620-014-3336-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
573 Wolffram I, Petroff D, Bätz O, Jedrysiak K, Kramer J, Tenckhoff H, Berg T, Wiegand J. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. Journal of Hepatology 2015;62:1256-64. [DOI: 10.1016/j.jhep.2015.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
574 Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR. Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B. J Korean Med Sci 2018;33:e11. [PMID: 29215820 DOI: 10.3346/jkms.2018.33.e11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
575 Saab S, Chen PY, Saab CE, Tong MJ. The Management of Hepatitis B in Liver Transplant Recipients. Clin Liver Dis 2016;20:721-36. [PMID: 27742010 DOI: 10.1016/j.cld.2016.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
576 Tsai TY, Hung TH, Livneh H, Lin IH, Lu MC, Yeh CC. Chinese herbal medicine therapy and the risk of mortality for chronic hepatitis B patients with concurrent liver cirrhosis: a nationwide population-based cohort study. Oncotarget 2018;9:18214-23. [PMID: 29719600 DOI: 10.18632/oncotarget.24383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
577 Jwa HY, Cho YK, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU, Kim BS, Lee BW, Song BC. Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis. Clin Mol Hepatol 2016;22:183-7. [PMID: 27044771 DOI: 10.3350/cmh.2016.22.1.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
578 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 11.9] [Reference Citation Analysis]
579 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
580 Su CW, Wu CY, Lin JT, Ho HJ, Wu JC. Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. J Chin Med Assoc 2020;83:125-33. [PMID: 32015266 DOI: 10.1097/JCMA.0000000000000247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Lejealle C, Castera L. Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Curr Hepatology Rep 2018;17:492-501. [DOI: 10.1007/s11901-018-0439-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
582 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
583 Liu K, Xiang X, Bao R, Chen R, Liu Y, Xie J, Guo Q, Bao S, Xie Q, Wang H. A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. Sci Rep 2016;6:28779. [PMID: 27364728 DOI: 10.1038/srep28779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
584 Wu S, Luo W, Wu Y, Chen H, Peng J. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases. BMC Gastroenterol. 2020;20:121. [PMID: 32316928 DOI: 10.1186/s12876-020-01263-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
585 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
586 Young K, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. J Viral Hepat. 2017;24:789-796. [PMID: 28273387 DOI: 10.1111/jvh.12703] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
587 Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274-276. [PMID: 21145419 DOI: 10.1016/j.cgh.2010.11.040] [Cited by in Crossref: 117] [Cited by in F6Publishing: 118] [Article Influence: 9.8] [Reference Citation Analysis]
588 Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1509-1517. [PMID: 31025388 DOI: 10.1111/apt.15269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
589 Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62:S15-24. [PMID: 25920084 DOI: 10.1016/j.jhep.2015.02.039] [Cited by in Crossref: 350] [Cited by in F6Publishing: 329] [Article Influence: 58.3] [Reference Citation Analysis]
590 Wong WCW, Lo YR, Jiang S, Peng M, Zhu S, Kidd MR, Wang XC, Chan PL, Ong JJ. Improving the hepatitis cascade: assessing hepatitis testing and its management in primary health care in China. Fam Pract 2018;35:731-7. [PMID: 29741661 DOI: 10.1093/fampra/cmy032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
591 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
592 Chakraborty JB, Oakley F, Walsh MJ. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol. 2012;2012:648915. [PMID: 22567408 DOI: 10.1155/2012/648915] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
593 Du X, Li H, Yang X, Li J, Xu J, Chen Y, Xu Q, Yang L, He C, Huang C, Meng X, Li J. Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis. International Immunopharmacology 2019;75:105671. [DOI: 10.1016/j.intimp.2019.05.056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
594 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
595 Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. J Viral Hepat. 2013;20:502-509. [PMID: 23730844 DOI: 10.1111/jvh.12054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
596 Huang Y, de Boer WB, Adams LA, MacQuillan G, Rossi E, Rigby P, Raftopoulos SC, Bulsara M, Jeffrey GP. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int 2013;33:1249-56. [PMID: 23617278 DOI: 10.1111/liv.12184] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
597 Guo YC, Lu LG. Antihepatic Fibrosis Drugs in Clinical Trials. J Clin Transl Hepatol 2020;8:304-12. [PMID: 33083254 DOI: 10.14218/JCTH.2020.00023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
598 Skupsky J, Hu K. Current hepatitis B treatment guidelines and future research directions. Front Med 2014;8:145-57. [DOI: 10.1007/s11684-014-0335-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
599 Piroth L, Pol S, Miailhes P, Lacombe K, Lopes A, Fillion A, Loustaud-Ratti V, Borsa-Lebas F, Salmon D, Rosenthal E, Carrat F, Cacoub P; GERMIVIC Study Group. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int 2015;35:1950-8. [PMID: 25559645 DOI: 10.1111/liv.12777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
600 Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
601 Lim Y, Han S, Heo N, Shim JH, Lee HC, Suh DJ. Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. Gastroenterology 2014;147:152-61. [DOI: 10.1053/j.gastro.2014.02.033] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 12.6] [Reference Citation Analysis]
602 Ward H, Tang L, Poonia B, Kottilil S. Treatment of hepatitis B virus: an update. Future Microbiol. 2016;11:1581-1597. [PMID: 27855500 DOI: 10.2217/fmb-2016-0128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
603 Hsu Y, Ho H, Lee T, Huang Y, Wu M, Lin J, Wu C, El‐serag HB. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat 2018;25:543-51. [DOI: 10.1111/jvh.12832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
604 Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol 2014; 20(23): 7169-7180 [PMID: 24966587 DOI: 10.3748/wjg.v20.i23.7169] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
605 Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
606 Zhang Q, Li G, Yu Y, Qiu C, Zheng J, Zhang H, Zhang M, Song Z, Yang Y, Du X, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Huang Y, Zhang J, Chen Z, Zhang W. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients. J Viral Hepat 2019;26 Suppl 1:59-68. [PMID: 31380588 DOI: 10.1111/jvh.13153] [Reference Citation Analysis]
607 Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients 2020;12:E2627. [PMID: 32872239 DOI: 10.3390/nu12092627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
608 Shen Y, Wu SD, Wu L, Wang SQ, Chen Y, Liu LL, Li J, Yang CQ, Wang JY, Jiang W. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int 2019;13:560-72. [PMID: 31273618 DOI: 10.1007/s12072-019-09952-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
609 Yang K, Guan SH, Zhang H, Pan Y, Wu YY, Wang AH, Sun BB. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-alpha therapy. Int J Mol Sci 2014;15:21286-98. [PMID: 25407531 DOI: 10.3390/ijms151121286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
610 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]